Company intelligence / Profile preview

Resonea

Scottsdale, Arizona, United States

Ownership: Private
Development stage: Commercial

Overview

The company developed the DROWZLE® platform for in-home screening and long-term management of obstructive sleep apnea and general sleep health. The FDA-cleared version provides prescription-based pre-screening for OSA using a smartphone app that analyzes respiratory patterns during sleep. Clinical results include successful FDA clearance as a Class II medical device in July 2019.

Therapeutic areas: Pulmonology
Modalities: DeviceSoftware (mobile app)Digital health tool
Industry: Digital Health Medical Devices

Partnerships

Arizona State University engineering department

Beyond the preview

Go deeper on Resonea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resonea.

Explore the full profile